论文部分内容阅读
目的探讨艾迪注射液联合化疗(NP方案)治疗晚期非小细胞肺癌中减毒、增效的临床作用。方法非小细胞肺癌患者76例,随机分为艾迪+化疗治疗组和单用化疗对照组。两组患者21d为1个疗程,连续化疗2个疗程以上。评定临床治疗效果,观察减轻副作用的效果。结果观察组化疗总有效率与对照组比较,差异有统计学意义(P<0.05);观察组骨髓抑制和消化道反应发生率与对照组比较,差异有统计学意义(P<0.05)结论艾迪注射液能够提高化疗(NP方案)治疗晚期非小细胞肺癌的临床效果,同时具有减轻化疗反应的作用。
Objective To investigate the clinical effect of Aidi Injection combined with chemotherapy (NP regimen) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 76 patients with non-small cell lung cancer were randomly divided into Aidi + chemotherapy group and chemotherapy alone group. Two groups of patients 21d for a course of treatment, continuous chemotherapy for more than 2 courses. To assess the effect of clinical treatment, observe the effect of reducing side effects. Results The total effective rate in observation group was significantly higher than that in control group (P <0.05). The incidence of bone marrow suppression and digestive tract reaction in observation group was significantly higher than that in control group (P <0.05) Di injection can improve the clinical efficacy of chemotherapy (NP regimen) in the treatment of advanced non-small cell lung cancer, while reducing the response to chemotherapy.